Waist Circumference Measurements in Schizophrenic Patients

Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01243034

Enrollment

Registered

2010-11-18

Start date

2010-08-01

Completion date

2011-07-31

Last updated

2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor, Schizophrenia, Waist Circumference Measurements

Brief summary

The prevalence of metabolic syndrome(MS) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. Schizophrenic patients with MS have an increased incidence of DM, coronary heart disease and increased mortality from cardiovascular diseases. Central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. Waist circumference(WC) is a better indicator of abdominal obesity and a better predictor of CVD than either BMI or waist-to-hip ratio. However, currently there is no standard location for the measurement of WC. Objectives: 1. To compare the magnitude of WC measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females. 2\. To examine the correlation of WC with Triglyceride, cholesterol, HDL, LDL and glucose.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* • Patients with schizophrenia or schizoaffective disorder (DSM-IV 295) age 18 till 65 years old. * Body weight change less than 1 kg in previous one month before index date.

Exclusion criteria

* • Patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days. * Patients received any anti-hypertensives or oral hypoglycemic agents. * Pregnant or breast-feeding women.

Countries

Taiwan

Outcome results